Actualités Apr 17, 2024 Addex Therapeutics lance la spin-off Neurosterix à Genève avec un investissement de USD 63 millions La société genevoise Addex Therapeutics s’est associée à Perceptive Advisors pour lancer la spin-off Neurosterix, un nouvel acteur dans le dévelo...
Aktuell May 10, 2024 BioVersys erweitert Serie-C-Runde auf 44,9 Millionen Franken BioVersys verstärkt die Zusammenarbeit mit GSK, um die Entwicklung von Alpibectir zur Behandlung von Tuberkulose zu beschleunigen. GSK beteiligt ...
Aktuell May 07, 2024 UZH forscht an neuer Krebstherapie Forschende der Universität Zürich (UZH) entwickeln neue Krebstherapeutika. Die sogenannten Radiotheranostika sollen Tumore gleichzeitig lokalisie...
News Apr 17, 2024 Addex Therapeutics launches spin-off Neurosterix in Geneva with USD 63 million investment Geneva's Addex Therapeutics has teamed up with Perceptive Advisors to launch spin-off Neurosterix, a new player in neurology-focused drug develop...
Aktuell Apr 03, 2024 Nouscom erhält weitere Mittel für Krebsimpfstoffe Nouscom hat eine Investition in der Höhe von 7 Millionen Euro von der italienischen Risikokapitalfirma Angelini Ventures erhalten. Damit kann das...
Aktuell Mar 27, 2024 TissueLabs startet Biofabrikation in Bellinzona TissueLabs sichert sich 800'000 Dollar und eröffnet ein neues Zentrum für Biofabrikation in Bellinzona. Die Mittel dienen der Verbesserung der ei...
News May 10, 2024 BioVersys extends Series C financing round to 44.9 million Swiss francs BioVersys is bolstering its partnership with GSK in order to accelerate the development of alpibectir for the treatment of tuberculosis. GSK is s...
News May 07, 2024 UZH researching innovative cancer therapy Researchers from the University of Zurich (UZH) are in the process of developing new cancer therapeutics. Known as radiotheranostics, these drugs...
News Mar 27, 2024 TissueLabs begins biofabrication activities in Bellinzona TissueLabs has secured investment of 800,000 US dollars and has opened a new biofabrication hub in Bellinzona in the canton of Ticino. The fresh ...
Aktuell Apr 04, 2024 Indivi spannt mit Biogen zusammen Indivi und Biogen wollen bei der Entwicklung digitaler Biomarker für die Parkinson-Krankheit kooperieren. Dafür lizenziert der amerikanische Biot...
News Sep 06, 2023 ten23 health boosts sterile production capacity and introduces new quality control services Renowned for its expertise in sterile drug product manufacturing, Valais-based ten23 health is taking significant steps to expand its services an...
News Feb 14, 2024 University of Fribourg discovers drug to combat age-related neuroinflammation Scientists at the University of Fribourg have uncovered a groundbreaking mechanism that could significantly mitigate age-related neuroinflammatio...
News Aug 07, 2023 CDR-Life receives milestone payment CDR-Life has reached a second milestone linked to the development of its drug to combat an irreversible retinal disease. This entitles the biotec...
News Apr 04, 2024 Indivi joins forces with Biogen Indivi and Biogen are cooperating on the development of digital biomarkers for Parkinson’s disease. To this end, the US biotech group is licensin...
Aktuell Aug 07, 2023 CDR-Life erhält Meilensteinzahlung CDR-Life hat bei der Entwicklung seines Therapeutikums gegen eine irreversible Erkrankung der Netzhaut ein zweites Etappenziel erreicht. Das bere...
News Apr 03, 2024 Nouscom receives additional funding for cancer vaccines Nouscom has received an investment totalling 7 million euros from the Italian venture capital firm Angelini Ventures. The Basel-based biotech com...
News Jan 22, 2024 DISCO Pharmaceuticals secures seed funding of 20 million euros DISCO Pharmaceuticals has secured seed funding of 20 million euros and officially launched the business. The team was the first to develop a meth...